Durvalumab, also known as Imfinzi and made by AstraZeneca, is recommended in final draft guidance for adults with limited-stage small cell lung cancer (SCLC). This is where the cancer is contained in ...

In the lead-up to World Duchenne Awareness Day (Sunday, 7 September), we’re pleased to announce the completion of our first assessment of an externally developed clinical guideline – marking a ...

Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.

Access to hybrid closed loop systems will be through a 5‑year phased roll out in line with NHS England's implementation plan. For enquiries about cost-effective pricing, contact Leigh.Carr@supplychain ...

This guideline has been updated and replaced by NICE guideline NG123.

Suggested remit: To appraise the clinical and cost effectiveness of nusinersen and risdiplam within their marketing authorisations for treating spinal muscular atrophy.

There are commercial access agreements for enfortumab vedotin and pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor ...

This guidance has been updated and replaced by NICE technology appraisal guidance TA798 ...

Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin within its marketing authorisation for treating relapsed or refractory multiple myeloma after 4 or more ...

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...

This guideline sets out an antimicrobial prescribing strategy for adults, young people and children aged 72 hours and over with impetigo. It aims to optimise antibiotic use and reduce antibiotic ...